VEGFA and kidney neoplasm: Our finding demonstrates that miR-106a-5p can represent a potential biomarker for ccRCC patients and increased miR-106a-5p levels can dramatically decrease the protein level of VEGFA in kidney tumor cells, consequently inhibiting tumor cell proliferation and leading to cell death.